Zilebesiran: A Paradigm Shift in Hypertension Management Through Biannual RNA Interference Therapy- A Literature Review

Hypertension is one of the largest challenges facing global public health, being a key driver for cardiovascular disease, stroke and chronic kidney disease ^[1]. Despite the wide array of pharmacologic agents that have been developed (“black magic pills” such as diuretics, ACE inhibitors/angiotensin receptor blockers, calcium channel blockers, beta-blockers), effective and sustained blood pressure control in routine clinical practice is still spotty for many of these hypertensive patients^[2].The main cause of this ongoing treatment gap is not the ineffectiveness of medications, but the patient's difficulty in consistently following long-term, frequently complicated, daily routines^[3]. Many elements contribute to this compliance hurdle, including the requirement for daily dosing and burden of polypharmacy, occurrence of drug-related side effects, and issue of therapeutic inertia—all which lead to poor patient engagement and ultimately sub-optimal efficacy in treating hypertension ^[4]. In light of this, the focus of development has shifted towards therapies capable of providing potent and sustained blood pressure lowering by new pharmacologic action, and importantly at lower frequency dosing ^[5].  This review consolidates the growing evidence base to better understand the clinical and mechanistic implications of zilebesiran’s potential role in treatment for hypertension examining its MOA, early-phase trial results, safety profile, along with implications for patient outcomes and health systems across the globe ^[6,7]. In so doing, this article seeks to provide a future-oriented view of how this approach may begin to alter the foundational landscape for hypertension management in years ahead. Fig.1outlines the clinical rationale and identified need for a novel agent like zilebesiran, as discussed in this introduction.

Fig.1. Conceptual Framework: The Unmet Need and Rationale for Zilebesiran in Hypertension Management.

2. Mechanism of Action of Zilebesiran

Zilebesiran employs RNA interference mechanisms to specifically lower hepatic synthesis of angiotensinogen, which is the precursor to angiotensin I and II in the renin–angiotensin–aldosterone system (RAAS)^[6]. Traditional RAAS inhibitors, including ACE inhibitors and angiotensin receptor blockers (ARBs), function downstream and are affected by compensatory physiological mechanisms ^[7]. Conversely, zilebesiran directly inhibits AGT mRNA, leading to a strong and prolonged decrease in plasma angiotensinogen levels. This upstream suppression results in a deeper and extended inhibition of the RAAS cascade. Research has shown that one subcutaneous injection can greatly reduce AGT for multiple months, resulting in consistent decreases in systolic and diastolic BP ^[8].

3. Pharmacokinetics and Pharmacodynamics

The pharmacokinetic characteristics of zilebesiran demonstrate its extended-action properties. After subcutaneous injection, zilebesiran undergoes swift hepatic absorption due to GalNAc conjugation, promoting targeted interaction with hepatocyte receptors^[9].The plasma levels decrease gradually, yet its molecular silencing impact lingers significantly longer than its measurable presence in the system^[10].Pharmacodynamic investigations show that AGT inhibition can persist for as long as six months in numerous patients, accompanied by proportional and expected decreases in circulating RAAS biomarkers^[6].In contrast to traditional antihypertensives, zilebesiran is minimally metabolized via cytochrome P450 pathways, lowering the risks of drug–drug interactions. Its extended PD profile also indicates that missed doses are improbable to cause rebound hypertension ^[11]. The combined pharmacokinetic and pharmacodynamic properties offer distinct clinical benefits, such as lower dosing frequency and steady blood pressure management ^[9,10].

4. Clinical Efficacy in Phase 1 and Phase 2 Trials

Initial clinical trials show notable and lasting reductions in blood pressure with zilebesiran. Phase 1 trials involving healthy volunteers indicated that plasma AGT levels decreased by more than 90% in a dose-dependent manner, with effects lasting for several months^[12].These reductions resulted in significant decreases in ambulatory systolic BP. Phase 2 trials, encompassing the KARDIA-1 and KARDIA-2 studies, broadened these results to individuals with hypertension, demonstrating that zilebesiran achieved prolonged BP reduction for a minimum of six months following a single administration^[6,12]. In KARDIA-1, doses of 300 mg and 600 mg led to significant decreases in average 24-hour systolic BP, with optimal effects seen approximately 8 to 12 weeks and sustained afterwards ^[6]. The response remained steady across various demographic groups, and numerous patients reached guideline recommended BP targets with monotherapy alone ^[13].

5. Combination Therapy and Add-On Potential

While zilebesiran shows strong effectiveness as a standalone treatment, multiple studies have explored its application alongside other antihypertensive medications ^[13]. Considering that hypertension typically necessitates various therapeutic approaches for effective management, the compatibility of zilebesiran with existing drug classes is crucial ^[14]. Studies assessing combination therapy involving ARBs, thiazide diuretics, and calcium channel blockers suggest that zilebesiran can be safely administered together without reducing effectiveness ^[13,11]. The KARDIA-2 trial demonstrated that zilebesiran sustained its RAAS-suppression effects when combined with background therapy, frequently resulting in larger BP reductions compared to standard therapy by itself ^[13]. Notably, zilebesiran did not seem to induce significant hypotension when combined with current medications, indicating a positive add-on profile. This adaptability enhances its possible function in practical hypertension treatment, where combination therapy is standard ^[14].

6. Safety and Tolerability Profile

In various clinical studies, zilebesiran has shown a promising safety profile. The frequently reported side effects include minor injection-site reactions, temporary redness, and slight fatigue, all of which go away on their own. Severe negative events are uncommon, and stopping treatment because of side effects is still low ^[12,6]. The focused hepatic mechanism decreases systemic exposure, minimizing the chances of off-target effects ^[6]. In contrast to ACE inhibitors, zilebesiran has not been linked to cough or angioedema ^[11]. Additionally, since it influences angiotensinogen instead of inhibiting ACE or AT1 receptors, the probability of hyperkalemia seems reduced; however, monitoring is still recommended, particularly for individuals with chronic kidney disease ^[12,6]. Significantly, prolonged RAAS suppression heightens theoretical worries about hypotension during dehydration or sickness, yet preliminary analyses indicate these occurrences are rare ^[6,13]. In general, the tolerability profile suggests that zilebesiran could be a potentially safer option compared to many primary antihypertensive medications ^[12].

7. Advantages Over Conventional Antihypertensives

Conventional antihypertensive medications necessitate daily administration and rely significantly on patient compliance for ongoing blood pressure management. Low adherence rates, estimated at around 50% after one year of treatment, markedly diminish treatment efficacy and elevate cardiovascular risk ^[14]. Zilebesiran tackles this issue by providing a biannual dosing regimen, which removes the need for daily pills ^[6]. Its mechanism also eliminates the highs and lows linked to oral medications, ensuring smoother and more stable BP regulation ^[11]. Additionally, zilebesiran’s extended duration minimizes the risks related to missed doses and might enhance long-term cardiovascular results ^[6,13]. In contrast to daily medications which often require several additional drugs, zilebesiran’s effectiveness and endurance could lessen the necessity for polypharmacy ^[13].

8. Potential Public Health Impact

The launch of a biannual injectable antihypertensive may significantly impact public health systems, particularly in areas with low medication adherence ^[15]. Extended-release therapies simplify treatment plans and may lower the frequency of uncontrolled hypertension, consequently decreasing the risk of stroke, heart attack, heart failure, and chronic kidney disease ^[16]. The straightforward dosing schedule could be especially advantageous for older adults, those with cognitive difficulties, and patients with multiple chronic conditions^[17].Additionally, administering treatment biannually fits seamlessly with organized healthcare appointments, enabling providers to achieve steady long-term BP management^[18].In settings with limited resources, where access to medication and its continuity pose significant challenges, a biannual treatment could enhance equity in care^[19].If widely adopted, zilebesiran could significantly lessen the worldwide burden of cardiovascular diseases. The consolidated evidence, summarized thematically in Table.1, supports the premise that zilebesiran could represent a paradigm shift in hypertension care ^[15,20].

Table 1 Summary of Key Evidence for Zilebesiran: Mechanisms, Efficacy, and Clinical Prospects.